The Claim

In Medicare Advantage beneficiaries with type 2 diabetes, initiating glucagon-like peptide-1 receptor agonists (GLP-1 RA) is associated with 9.0% higher pharmacy costs and 5.7% higher total health care costs over 12 months compared to initiating sodium-glucose cotransporter-2 inhibitors (SGLT2i), with no difference in hospitalizations or emergency department visits.

Source: Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
67score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

Among Medicare Advantage patients with type 2 diabetes, starting GLP-1 RA medications results in 9.0% higher drug costs and 5.7% higher overall health care costs over one year compared to starting SGLT2i medications, with no difference in hospital or emergency room use.

See the scientific wording

In Medicare Advantage beneficiaries with type 2 diabetes, initiating glucagon-like peptide-1 receptor agonists (GLP-1 RA) is associated with 9.0% higher pharmacy costs and 5.7% higher total health care costs over 12 months compared to initiating sodium-glucose cotransporter-2 inhibitors (SGLT2i), despite no difference in hospitalizations or emergency department visits, indicating that higher drug prices drive increased overall spending without reducing acute care utilization.

Why this might work

GLP-1 receptor agonists cost more to produce and distribute than sodium-glucose cotransporter-2 inhibitors, so when patients start taking them, their pharmacy bills go up. Since both drugs work similarly to control blood sugar and neither causes more hospital visits or emergency trips, the higher total health care costs come only from the more expensive pills.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors.

    The study found that older adults with diabetes who started GLP-1 RA drugs paid more for their pills and had slightly higher total medical bills than those who started SGLT2i drugs, but they didn’t go to the hospital or ER more often — just like the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.